While BNP and NT-proBNP are recommended by the American and European Heart Associations as biomarkers for the diagnosis and prediction of heart failure, recombinant BNP is used in the treatment of heart failure because of its cardioprotective effects (Heidenreich et al., 2022; McDonagh et al., 2021). This evidence concerns the gene NPPB and heart failure.